Healthcare organizations face challenges in integrating rapidly expanding genomic information into clinical workflows. Lack of efficient tools for clinical decision support and patient education at the point of care hinders the effective implementation and scaling of genomic programs. This can lead to delays in patient management and suboptimal utilization of genomic insights.

Nest is a software platform designed to bring genomic information directly to the point of care, providing healthcare organizations with the infrastructure needed to launch and scale longitudinal genomic programs. The platform offers a comprehensive solution encompassing patient identification, clinical decision support, and tailored educational resources for both providers and patients. By integrating with existing Electronic Medical Records (EMRs), Nest allows providers to access decision support seamlessly, minimizing disruption and maximizing impact. The platform also facilitates coordinated genomic care by connecting patients, providers, and navigators, ensuring informed decision-making throughout the entire genomic care journey.

Integration with existing EMR systems for seamless access to decision support at the point of care.

Clinical Decision Support (CDS) tools that provide evidence-based recommendations based on patient genomic data.

Patient identification module to efficiently identify candidates for genomic testing and screening.

Tailored educational resources for providers and patients to enhance understanding of genomic information.

Robust analytics dashboard providing visibility into patient navigation, performance metrics, and ROI.

Modular design allowing customization of functionalities to fit the unique needs of different clinics and health systems.

Secure and HIPAA-compliant data handling to protect sensitive patient information.

Nest primarily targets healthcare organizations, including clinics and health systems, seeking to implement and scale genomic programs efficiently.

Nest generates revenue through software licensing fees and subscription-based access to its platform and associated services.